Predicted 25-hydroxyvitamin D score and incident type 2 diabetes in the Framingham Offspring Study.

Enju Liu, James B Meigs, Anastassios G Pittas, Christina D Economos, Nicola M McKeown, Sarah L Booth, Paul F Jacques
Author Information
  1. Enju Liu: Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, MA 02111, USA.

Abstract

BACKGROUND: Accumulating evidence suggests that vitamin D is involved in the development of type 2 diabetes (T2D).
OBJECTIVE: Our objective was to examine the relation between vitamin D status and incidence of T2D.
DESIGN: We used a subsample of 1972 Framingham Offspring Study participants to develop a regression model to predict plasma 25-hydroxyvitamin D [25(OH)D] concentrations from age, sex, body mass index, month of blood sampling, total vitamin D intake, smoking status, and total energy intake. Using this model, we calculated the predicted 25(OH)D score for each nondiabetic participant at the cohort's fifth examination to assess the association between the predicted 25(OH)D score and incidence of T2D by using Cox proportional hazards models.
RESULTS: A total of 133 T2D cases were identified over a 7-y average follow-up. In comparison with individuals in the lowest tertile of the predicted 25(OH)D score at baseline, those in the highest tertile had a 40% lower incidence of T2D after adjustment for age, sex, waist circumference, parental history of T2D, hypertension, low HDL cholesterol, elevated triglycerides, impaired fasting glucose, and Dietary Guidelines for Americans Adherence Index score (hazard ratio: 0.60; 95% CI: 0.37, 0.97; P for trend = 0.03).
CONCLUSIONS: Our findings suggest that higher vitamin D status is associated with decreased risk of T2D. Maintaining optimal 25(OH)D status may be a strategy to prevent the development of T2D.

References

  1. Am J Clin Nutr. 2004 May;79(5):820-5 [PMID: 15113720]
  2. J Clin Endocrinol Metab. 2002 Feb;87(2):666-74 [PMID: 11836302]
  3. Epidemiology. 2008 Sep;19(5):666-71 [PMID: 18496468]
  4. J Endocrinol Invest. 1988 Sep;11(8):577-84 [PMID: 3072373]
  5. Metabolism. 2000 Nov;49(11):1501-5 [PMID: 11092519]
  6. J Steroid Biochem Mol Biol. 2003 Feb;84(2-3):223-30 [PMID: 12711007]
  7. Arch Intern Med. 1979 Aug;139(8):857-61 [PMID: 464698]
  8. Diabetologia. 1995 Oct;38(10):1239-45 [PMID: 8690178]
  9. J Clin Endocrinol Metab. 2007 Jun;92(6):2017-29 [PMID: 17389701]
  10. Diabetes. 1981 May;30(5):382-6 [PMID: 7014306]
  11. Am J Epidemiol. 1992 May 15;135(10):1114-26; discussion 1127-36 [PMID: 1632423]
  12. Circulation. 2005 Oct 25;112(17):2735-52 [PMID: 16157765]
  13. Am J Clin Nutr. 1997 Oct;66(4):929-36 [PMID: 9322570]
  14. Diabetes Care. 2007 Apr;30(4):980-6 [PMID: 17277040]
  15. Clin Chim Acta. 1987 Jun 30;166(1):1-8 [PMID: 3608193]
  16. World Health Organ Tech Rep Ser. 1980;646:1-80 [PMID: 6771926]
  17. Endocrinology. 1986 Jul;119(1):84-90 [PMID: 3013599]
  18. Arch Intern Med. 2007 May 28;167(10):1068-74 [PMID: 17533210]
  19. Osteoporos Int. 1999;9(5):394-7 [PMID: 10550457]
  20. Endocr Rev. 1989 Feb;10(1):3-26 [PMID: 2666110]
  21. Diabetes Care. 2007 Jun;30(6):1549-55 [PMID: 17351276]
  22. Diabetes Care. 2006 Mar;29(3):650-6 [PMID: 16505521]
  23. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S [PMID: 15585789]
  24. J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [PMID: 16595781]
  25. Diabetes Care. 2008 Apr;31(4):701-7 [PMID: 18235052]
  26. Endocr J. 2000 Aug;47(4):383-91 [PMID: 11075718]
  27. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S [PMID: 15585788]
  28. Prev Med. 1975 Dec;4(4):518-25 [PMID: 1208363]
  29. Diabetes Care. 2007 Oct;30(10):2569-70 [PMID: 17626891]
  30. Eur J Clin Nutr. 1999 Dec;53(12):920-6 [PMID: 10602348]
  31. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1710S-6S [PMID: 15585792]
  32. Diabetes Care. 2004 Dec;27(12):2813-8 [PMID: 15562190]
  33. J Nutr. 2006 Nov;136(11):2908-15 [PMID: 17056821]
  34. N Engl J Med. 2007 Jul 19;357(3):266-81 [PMID: 17634462]
  35. Horm Res. 2006;66(5):211-5 [PMID: 16900001]
  36. Endocrinology. 1994 Apr;134(4):1602-10 [PMID: 8137721]
  37. Diabetologia. 1986 Mar;29(3):142-5 [PMID: 3516771]
  38. Am J Clin Nutr. 1993 Feb;57(2):182-9 [PMID: 8424386]
  39. Osteoporos Int. 2006 Dec;17(12):1742-8 [PMID: 16932872]
  40. Eur J Clin Nutr. 2009 Apr;63(4):458-64 [PMID: 18030310]
  41. Am J Epidemiol. 1985 Jul;122(1):51-65 [PMID: 4014201]
  42. Endocrinology. 1983 Oct;113(4):1511-8 [PMID: 6352248]
  43. Clin Chem. 1982 Jun;28(6):1379-88 [PMID: 7074948]
  44. Bone. 2008 May;42(5):996-1003 [PMID: 18329355]
  45. Am J Clin Nutr. 2007 Mar;85(3):755-61 [PMID: 17344497]
  46. J Am Diet Assoc. 1993 Jul;93(7):790-6 [PMID: 8320406]

Grants

  1. N01-HC-25195/NHLBI NIH HHS
  2. K24 DK080140/NIDDK NIH HHS
  3. R21 DK078867/NIDDK NIH HHS
  4. AG14759/NIA NIH HHS
  5. R01DK076092/NIDDK NIH HHS
  6. R21DK078867/NIDDK NIH HHS

MeSH Term

Blood Glucose
Blood Pressure
Cholesterol
Cohort Studies
Diabetes Mellitus, Type 2
Female
Glucose Tolerance Test
Humans
Male
Middle Aged
Models, Biological
Models, Statistical
Triglycerides
Vitamin D

Chemicals

Blood Glucose
Triglycerides
Vitamin D
Cholesterol
25-hydroxyvitamin D

Word Cloud

Created with Highcharts 10.0.0DT2DOHscorevitaminstatus250incidencetotalpredicteddevelopmenttype2diabetesFraminghamOffspringStudymodel25-hydroxyvitaminagesexintaketertileBACKGROUND:AccumulatingevidencesuggestsinvolvedOBJECTIVE:objectiveexaminerelationDESIGN:usedsubsample1972participantsdevelopregressionpredictplasma[25D]concentrationsbodymassindexmonthbloodsamplingsmokingenergyUsingcalculatednondiabeticparticipantcohort'sfifthexaminationassessassociationusingCoxproportionalhazardsmodelsRESULTS:133casesidentified7-yaveragefollow-upcomparisonindividualslowestbaselinehighest40%loweradjustmentwaistcircumferenceparentalhistoryhypertensionlowHDLcholesterolelevatedtriglyceridesimpairedfastingglucoseDietaryGuidelinesAmericansAdherenceIndexhazardratio:6095%CI:3797Ptrend=03CONCLUSIONS:findingssuggesthigherassociateddecreasedriskMaintainingoptimalmaystrategypreventPredictedincident

Similar Articles

Cited By